Is the price fair?
What IDXX's price assumes
Idexx Laboratories trades at 38.9× earnings against 35.3× for the median Diagnostics & Research name, more expensive than its own group.
38.9
Trailing P/E · Diagnostics & Research median 35.3 · 1.10× the median: the market pays up for this one
- Price / sales
- 10.1
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.8%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered +28% a year over the last three.
Details›
- Price / book2026-Q1
- 28.9
- EV / EBIT2026-Q1
- 32.1
- EV / sales2026-Q1
- 10.2
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $1.25B
- Market capitalisation
- $44.3B
- 3-year revenue growth
- +9.0%
- 3-year free cash flow growth
- +28%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $713.80 |
| Its own P/E history, median | $763.00 |
| Its own P/E history, upper quartile | $823.41 |
| 52-week range | $528.68 – $766.68 |
| Today | $553.16 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #10 of 29 by Smart Score